Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for ...

Veru (NASDAQ:VERU – Get Free Report) is expected to be releasing its earnings data before the market opens on Thursday, February 6th. Analysts expect Veru to post earnings of ($0.08) per share and ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

HR+/HER2- breast cancer is the most prevalent subtype of breast cancer, defined by cancer cells that possess hormone receptors for estrogen and/or progesterone but lack HER2 overexpression. This ...

CARLSBAD, Calif. - ImpediMed, known for its medical technology in fluid and body composition monitoring, has secured a five-year $15 million growth capital facility with SWK Holdings Corporation ...

A global pharmaceutical company partnered with DelveInsight to create a robust and simplified solution enabling its top executives to monitor the evolving breast cancer competitive intelligence ...

Veruschka Foundation trains people with developmental disabilities in culinary and essential life skills that will help them ...

Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the ...

Curently the only available blood test to tell which women are at risk of postpartum depression (PPD) is the one that ...

Yesterday, 168 employees from the US Environmental Protection Agency (EPA) office of environmental justice were placed on administrative leave, the New York Times reports. The newspaper continues: ...

Craig Morgan outlines why comparator clinical trials are useful and provides points to consider to ensure the best outcome. In clinical trials, a comparator drug (defined as ‘an investigational ...